Brief: Puma Biotechnology Presents Updated Findings From The TBCRC-022 Trial At The 2022 San Antonio Breast Cancer Symposium
07/12/2022 23:07
Dec 7 (Reuters) - Puma Biotechnology Inc PBYI.O :
* PUMA BIOTECHNOLOGY PRESENTS UPDATED FINDINGS FROM THE
TBCRC-022
TRIAL AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM
Source text for Eikon: ID:nBw9Vdx4Xa
Further company coverage: PBYI.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Puma Biotechnology
See all newsBrief: Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.2